US 11,939,382 B2
Bispecific PD-1 and TIGIT binding proteins and uses thereof
Yariv Mazor, Gaithersburg, MD (US); Yue Wang, Gaithersburg, MD (US); Gordon Moody, Gaithersburg, MD (US); Deepali Malhotra, Gaithersburg, MD (US); Michael Overstreet, Gaithersburg, MD (US); Eleanor Clancy-Thompson, Gaithersburg, MD (US); Karin Lee, Gaithersburg, MD (US); Stacy Pryts, Gaithersburg, MD (US); and Scott Hammond, Gaithersburg, MD (US)
Assigned to MedImmune, LLC, Gaithersburg, MD (US)
Filed by MedImmune, LLC, Gaithersburg, MD (US)
Filed on Apr. 29, 2022, as Appl. No. 17/661,307.
Claims priority of provisional application 63/182,156, filed on Apr. 30, 2021.
Prior Publication US 2022/0411509 A1, Dec. 29, 2022
Int. Cl. C07K 16/28 (2006.01); A61K 39/395 (2006.01); A61K 45/06 (2006.01); A61P 35/00 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/2818 (2013.01) [A61K 39/39558 (2013.01); A61K 45/06 (2013.01); A61P 35/00 (2018.01); C07K 16/2803 (2013.01); A61K 2039/505 (2013.01); C07K 2317/31 (2013.01); C07K 2317/565 (2013.01); C07K 2317/72 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01)] 20 Claims
OG exemplary drawing
 
1. A bispecific binding protein that specifically binds to PD-1 and TIGIT comprising:
a) a first binding domain that specifically binds to PD-1, wherein the first binding domain comprises a heavy chain variable domain comprising a HCDR1 comprising the amino acid sequence of SEQ ID NO: 1, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 2, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 3, and a light chain variable domain comprising a LCDR1 comprising the amino acid sequence of SEQ ID NO: 4, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 5 and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 6; and
b) a second binding domain that specifically binds to TIGIT, wherein the second binding domain comprises a heavy chain variable domain comprising a HCDR1 comprising the amino acid sequence of SEQ ID NO: 11, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 12, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 13, and a light chain variable domain comprising a LCDR1 comprising the amino acid sequence of SEQ ID NO: 14, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 15, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 16.